FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023340565> ?p ?o ?g. }

• W2023340565 endingPage "102" @default.
• W2023340565 startingPage "91" @default.
• W2023340565 abstract "Guinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway hyper-reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model.The aim of this study was to establish a conscious guinea-pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti-asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase-4 (PDE4) inhibitor, rolipram.Guinea-pigs were sensitized with ovalbumen (OA) (10 microg plus Al2(OH)3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 microg/mL) or vehicle for 1 h. Airway function was measured by whole-body plethysmography as specific airway conductance (sGaw). Reactivity to inhaled histamine (nose-only, 1 mm, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine.Guinea-pigs challenged with OA showed an EAR as a fall in (sGaw) (-54.9+/-10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (-30.2+/-8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sGaw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3- and 44-fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR.This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti-asthmatic activity by the PDE4 inhibitor, rolipram." @default.
• W2023340565 created "2016-06-24" @default.
• W2023340565 creator A5033149647 @default.
• W2023340565 creator A5049540374 @default.
• W2023340565 date "2004-01-01" @default.
• W2023340565 modified "2023-10-15" @default.
• W2023340565 title "Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram" @default.
• W2023340565 cites W1498706619 @default.
• W2023340565 cites W1499836599 @default.
• W2023340565 cites W1524157627 @default.
• W2023340565 cites W1538833583 @default.
• W2023340565 cites W1964774361 @default.
• W2023340565 cites W1967805987 @default.
• W2023340565 cites W1974726443 @default.
• W2023340565 cites W1978538090 @default.
• W2023340565 cites W1988517724 @default.
• W2023340565 cites W2000470005 @default.
• W2023340565 cites W2004778304 @default.
• W2023340565 cites W2009114097 @default.
• W2023340565 cites W2025217626 @default.
• W2023340565 cites W2027455597 @default.
• W2023340565 cites W2033576477 @default.
• W2023340565 cites W2042027156 @default.
• W2023340565 cites W2043504885 @default.
• W2023340565 cites W2047555050 @default.
• W2023340565 cites W2088116433 @default.
• W2023340565 cites W2094902000 @default.
• W2023340565 cites W2114151186 @default.
• W2023340565 cites W2122227124 @default.
• W2023340565 cites W2129186256 @default.
• W2023340565 cites W2137200414 @default.
• W2023340565 cites W2138337206 @default.
• W2023340565 cites W2155775855 @default.
• W2023340565 cites W2161378587 @default.
• W2023340565 cites W2169303799 @default.
• W2023340565 cites W4255839776 @default.
• W2023340565 doi "https://doi.org/10.1111/j.1365-2222.2004.01833.x" @default.
• W2023340565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14720268" @default.
• W2023340565 hasPublicationYear "2004" @default.
• W2023340565 type Work @default.
• W2023340565 sameAs 2023340565 @default.
• W2023340565 citedByCount "42" @default.
• W2023340565 countsByYear W20233405652012 @default.
• W2023340565 countsByYear W20233405652013 @default.
• W2023340565 countsByYear W20233405652014 @default.
• W2023340565 countsByYear W20233405652015 @default.
• W2023340565 countsByYear W20233405652016 @default.
• W2023340565 countsByYear W20233405652017 @default.
• W2023340565 countsByYear W20233405652019 @default.
• W2023340565 countsByYear W20233405652020 @default.
• W2023340565 crossrefType "journal-article" @default.
• W2023340565 hasAuthorship W2023340565A5033149647 @default.
• W2023340565 hasAuthorship W2023340565A5049540374 @default.
• W2023340565 hasConcept C1122143 @default.
• W2023340565 hasConcept C126322002 @default.
• W2023340565 hasConcept C134018914 @default.
• W2023340565 hasConcept C147483822 @default.
• W2023340565 hasConcept C181199279 @default.
• W2023340565 hasConcept C185592680 @default.
• W2023340565 hasConcept C203014093 @default.
• W2023340565 hasConcept C2776042228 @default.
• W2023340565 hasConcept C2776946954 @default.
• W2023340565 hasConcept C2776954882 @default.
• W2023340565 hasConcept C2776958096 @default.
• W2023340565 hasConcept C2777037409 @default.
• W2023340565 hasConcept C2777714996 @default.
• W2023340565 hasConcept C2777961210 @default.
• W2023340565 hasConcept C2780401358 @default.
• W2023340565 hasConcept C2780769369 @default.
• W2023340565 hasConcept C42219234 @default.
• W2023340565 hasConcept C519581460 @default.
• W2023340565 hasConcept C55493867 @default.
• W2023340565 hasConcept C62826618 @default.
• W2023340565 hasConcept C71924100 @default.
• W2023340565 hasConcept C98274493 @default.
• W2023340565 hasConceptScore W2023340565C1122143 @default.
• W2023340565 hasConceptScore W2023340565C126322002 @default.
• W2023340565 hasConceptScore W2023340565C134018914 @default.
• W2023340565 hasConceptScore W2023340565C147483822 @default.
• W2023340565 hasConceptScore W2023340565C181199279 @default.
• W2023340565 hasConceptScore W2023340565C185592680 @default.
• W2023340565 hasConceptScore W2023340565C203014093 @default.
• W2023340565 hasConceptScore W2023340565C2776042228 @default.
• W2023340565 hasConceptScore W2023340565C2776946954 @default.
• W2023340565 hasConceptScore W2023340565C2776954882 @default.
• W2023340565 hasConceptScore W2023340565C2776958096 @default.
• W2023340565 hasConceptScore W2023340565C2777037409 @default.
• W2023340565 hasConceptScore W2023340565C2777714996 @default.
• W2023340565 hasConceptScore W2023340565C2777961210 @default.
• W2023340565 hasConceptScore W2023340565C2780401358 @default.
• W2023340565 hasConceptScore W2023340565C2780769369 @default.
• W2023340565 hasConceptScore W2023340565C42219234 @default.
• W2023340565 hasConceptScore W2023340565C519581460 @default.
• W2023340565 hasConceptScore W2023340565C55493867 @default.
• W2023340565 hasConceptScore W2023340565C62826618 @default.
• W2023340565 hasConceptScore W2023340565C71924100 @default.
• W2023340565 hasConceptScore W2023340565C98274493 @default.
• W2023340565 hasIssue "1" @default.

• next